Clinical efficacy of immune checkpoint inhibitor plus vascular endothelial growth factor inhibitor in the first-line treatment of advanced unresectable hepatocellular carcinoma
10.3760/cma.j.cn115610-20220824-00469
- VernacularTitle:免疫检查点抑制剂联合血管内皮生长因子抑制剂一线治疗晚期不可切除肝细胞癌的临床疗效
- Author:
Hu QIU
1
;
Shaobo KE
;
Gaoke CAI
;
Yongshun CHEN
Author Information
1. 武汉大学人民医院肿瘤中心，武汉 430060
- Keywords:
Liver neoplasms;
Immunotherapy;
Programmed death ligand-1 inhibitor;
Vascular endothelial growth factor inhibitor;
Combination therapy
- From:
Chinese Journal of Digestive Surgery
2022;21(S1):29-34
- CountryChina
- Language:Chinese
-
Abstract:
In the past decade, rapid breakthroughs have been made in the systemic treat-ment of advanced unresectable hepatocellular carcinoma. Single systemic therapy has little effect on controlling tumor local recurrence and distant metastasis, and the combination modality therapy is the treatment for the majority of patients with advanced hepatocellular carcinoma. The change of tumor microenvironment is the research hotspot of antitumor therapy at present. Targeted therapy, immunotherapy and radiotherapy can lead to a change in the tumor microenvironment of primary hepatic carcinoma. The synergistic effect of combined therapy is particularly important. The authors report the clinical efficacy of programmed death ligand-1 inhibitor plus vascular endothelial growth factor inhibitor in the first-line treatment of a patient with advanced unresectable hepatocellular carci-noma. The results show that partial response being achieved according to the modified response evaluation criteria in solid tumors, and the survival time is more than 20 months with no obvious adverse reactions and high quality of life.
